Zobrazeno 1 - 10
of 24
pro vyhledávání: '"M E, Nga"'
Autor:
Gregory P. Sadler, Susan A. Brooks, M. E. Nga, Kee Yuan Ngiam, G. S. T. Soon, W. B. Tan, Radu Mihai, Rajeev Parameswaran
Publikováno v:
BJS Open. 2:353-359
Background Aberrant glycosylation is a hallmark of cancer cells and plays an important role in oncogenesis and cancer progression including metastasis. This study aimed to assess alteration in cellular glycosylation, detected by lectin Helix pomatia
Autor:
R, Parameswaran, W B, Tan, M E, Nga, G S T, Soon, K Y, Ngiam, S A, Brooks, G P, Sadler, R, Mihai
Publikováno v:
BJS open. 2(5)
Aberrant glycosylation is a hallmark of cancer cells and plays an important role in oncogenesis and cancer progression including metastasis. This study aimed to assess alteration in cellular glycosylation, detected by lectin Helix pomatia agglutinin
Publikováno v:
Cytopathology. 29:i-i
Publikováno v:
Cytopathology. 28:i-i
Autor:
D G-S Lim, S.S. Ng, Thomas Paulraj Thamboo, A R Chang, Alvin Soon Tiong Lim, L H-C Tan, M-E Nga, S-L Tien
Publikováno v:
Histopathology. 53:120-122
Autor:
M E, Nga, B, Amanuel
Publikováno v:
Cytopathology : official journal of the British Society for Clinical Cytology. 24(5)
Publikováno v:
Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia. 20(2)
Autor:
M. E. Nga, G. C. Raju
Publikováno v:
Pathology. 35:170-172
Autor:
B, Pang, M, Dettmer, D, Matthias, C W, Ong, A N, Dhewar, S, Gupta, G L, Lim, M E, Nga, J E, Seet, A, Qasim, T M, Chin, R, Soo, R, Soong, M, Salto-Tellez
Publikováno v:
Cytopathology : official journal of the British Society for Clinical Cytology. 23(4)
To compare the rejection rates of non-small cell lung cancer (NSCLC) samples obtained by differing sampling methods for testing by Sanger sequencing for epidermal growth factor receptor (EGFR) mutations. To assess the association between unsatisfacto
Publikováno v:
Cytopathology : official journal of the British Society for Clinical Cytology. 22(6)
Sanger sequencing is one of several reliable methods in use to detect KRAS and BRAF mutations to facilitate clinical patient selection for anti-epidermal growth factor receptor (EGFR) monoclonal antibody therapy in unresectable metastatic colorectal